ReportGem ReportGem

U.S. COMPANY FILING

3Q25 FORM 10-Q

Filed: 2025-11-05Company: Merck & Co., Inc.Ticker: MRKExchange: NYSEForm: 10-QReport period: 2025-09-30SEC accession: 0000310158-25-000059Event: earningsMateriality: 85

Filing text preview

Merck's Q3 2025 sales rose 4% to $17.28B, with nine-month sales of $48.61B. Net income increased 14% to $15.30B. R&D expenses declined due to prior-year acquisition charges. Issued $6B notes to fund Verona Pharma acquisition. Alliance revenue with AstraZeneca grew, especially Koselugo. Legal risks include Capvaxive patent litigation.

This preview uses text already stored in ReportGem and does not fetch the document from object storage during SEO generation. Review the internal filing record and the official SEC source before relying on it.

Open filing record

Related research and intelligence

Official SEC filing2025-11-05Merck and Moderna's Melanoma Vaccine Trial Positive, Vaccine Themed ETFs Surge2026-08-20S&P 500 and Nasdaq Edge Higher, Led by Moderna and Merck2026-08-2010-Q2026-08-07 · 10-QFORM 8-K2026-08-04 · 8-K1Q26 FORM 10-Q2026-05-04 · 10-QFORM 8-K2026-04-30 · 8-K10-K FOR THE FISCAL YEAR ENDED DECEMBER 31, 20252026-02-24 · 10-K